- Enabled Technologies
- RNA Interference (RNAi) technologies
- RNA antisense technologies
- Enabling technologies
- Linear amplification
RNA Therapeutics market is poised to grow at a significant rate due to an increase in the prevalence of chronic diseases such as cancer and cardiovascular diseases, surge in number of biopharmaceutical and biotechnology industries, Â rise in funding for the development of RNA therapeutics from public and private sectors, promising pipeline drugs, and wide range of applications with RNA therapeutics are the major factors that are driving the growth of the global RNA therapeutics market over the forecast timeframe. Players focusing on innovation of newer products and collaboration strategies to retain market position in global RNA therapeutics market. For instance, In August 2018, US Food and Drug Administration approved the first RNA interference (RNAi) therapeutic, a treatment for polyneuropathy caused by transthyretin (TTR) amyloidosis from Alnylam Pharmaceuticals. The report gives comprehensive outlook on RNA therapeutics across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report gives historical, current, and future market sizes (US$ Mn) on the basis of technology, application, route of administration, end user, and region. This report studies market dynamics elaborately to indentify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global RNA therapeutics products.
Fastest Growing Market
Increase in the prevalence of cancer, cardiovascular, and other chronic diseases is a key factor drive the global RNA therapeutics market. According to World Health Organization 2018, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, according to WHO, approximately 17.9 Mn deaths occurred due to cardiovascular disorders around the globe. In addition, target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models are anticipated to propel the global RNA therapeutics market over the forecast years.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.